Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation

Status Completed

Clinical Trial Summary

The overall aim of the clinical investigation is to confirm clinical performance, treatment satisfaction, adherence and safety of Actiste 1.0 and the Companion - Page 1 of 5 - app with TBL Backend when used by subjects with diabetes in need of insulin treatment. Primary objective: To assess diabetes treatment satisfaction in subjects with diabetes type 1 or type 2 in need of insulin treatment when using Actiste 1.0 and the Companion app with TBL Backend Secondary objective: To assess clinical performance and treatment adherence in subjects with diabetes type 1 or type 2 in need of insulin treatment when using Actiste 1.0 and the Companion app with TBL Backend

Clinical Trial Description

This is a prospective, single-arm, post-market clinical investigation to verify clinical performance, treatment satisfaction, adherence and safety of Actiste 1.0 and the Companion app with TBL Backend, referred to as Actiste diabetes management system (ADMS) when used as intended by subjects diagnosed with Diabetes Mellitus Type 1 or Type 2 (T1DM or T2DM). In total, 70 subjects diagnosed with T1DM or T2DM (35 subjects per type) using Glargine U100 basal insulin with or without oral antidiabetic drugs/bolus insulin regimen will be enrolled at 1 site in the UK. Each subject will be evaluated during a period of 6 months. Eight (8) visits are planned for each subject during the clinical investigation, including 3 visits to the study clinic and 5 visits conducted as telephone calls. During the visits, evaluations will be performed to assess blood glucose levels, adherence to the treatment plan, quality of life and treatment satisfaction. Data on blood glucose values, insulin injections and diabetesrelated data from the Companion app and TBL Backend will be shared by the subject.Each participant will be provided with the ADMS, including Actiste 1.0, and the Companion app for their smartphone with the TBL Backend. No comparator will be used. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05284071
Study type	Interventional
Source	Northern Care Alliance NHS Foundation Trust
Contact
Status	Completed
Phase	N/A
Start date	March 14, 2022
Completion date	December 21, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04101669` - EndoBarrier System Pivotal Trial(Rev E v2)	N/A
Recruiting	`NCT04164602` - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Completed	`NCT05915338` - Training on Using ıInsulin in Patients With Type 2 Diabetes
Not yet recruiting	`NCT04998461` - Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells
Not yet recruiting	`NCT04880005` - Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid	N/A
Recruiting	`NCT05365529` - Time-Restricted Eating for Type II Diabetes: TRE-T2D	N/A
Recruiting	`NCT03958591` - Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification	Phase 4
Recruiting	`NCT05501093` - Diabetes Reversal and the Subgingival Microbiota
Active, not recruiting	`NCT05784220` - The Canadian Diabetes Prevention Program	N/A
Active, not recruiting	`NCT04286555` - Dietary Approaches to Stop Hypertension for Diabetes	N/A
Completed	`NCT05076656` - Epigenetic and Microbiota Modifications	Early Phase 1
Completed	`NCT04423302` - Effect of Totum-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia (REVERSE-IT)	N/A
Completed	`NCT05928637` - A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150	Phase 1
Active, not recruiting	`NCT04660630` - A Real World Research: Comparison of Precision and Experience Therapy for Hypertension, Diabetes or Hyperlipidemias	N/A
Recruiting	`NCT03435328` - Hyposalivation Response To Transcutaneous Electrical Nerve Stimulation In Diabetic Type 2 Patients	N/A
Recruiting	`NCT04447859` - 16-week Flexible vs. 8-week Semaglutide Titration	Phase 3
Not yet recruiting	`NCT03968354` - NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)
Terminated	`NCT04819256` - Primary Care Based Integrated Community Care Team Intervention	N/A
Recruiting	`NCT05629221` - Organisational Models Supported by Technology for the Management of Diabetic Disease and Its Complications in a Diabetic Clinic Setting. A Randomised Controlled Trial Targeting Type 2 Diabetes Individuals With Non-ideal Glycemic Values	N/A
Completed	`NCT05260983` - Acceptance and Commitment Therapy Principles for Diabetes Prevention	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation — ADMSUK01

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms